LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Labetalol Hydrochloride In Sodium Chloride patents expire, and what generic alternatives are available?
Labetalol Hydrochloride In Sodium Chloride is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Labetalol Hydrochloride In Sodium Chloride
A generic version of LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE was approved as labetalol hydrochloride by HERITAGE PHARMA on August 3rd, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE?
- What are the global sales for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE?
- What is Average Wholesale Price for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE?
Summary for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 69 |
| DailyMed Link: | LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE at DailyMed |
Recent Clinical Trials for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boston Medical Center | Phase 4 |
| Marshall University | Phase 2 |
| Loma Linda University | N/A |
See all LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE clinical trials
Pharmacology for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE | labetalol hydrochloride | SOLUTION;INTRAVENOUS | 213330-002 | Nov 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hikma | LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE | labetalol hydrochloride | SOLUTION;INTRAVENOUS | 213330-003 | Nov 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hikma | LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE | labetalol hydrochloride | SOLUTION;INTRAVENOUS | 213330-004 | Nov 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
